TCR-like CARs and TCR-CARs targeting neoepitopes: an emerging potential

Neoepitopes or neoantigens are a spectrum of unique mutations presented in a particular patient's tumor. Neoepitope-based adoptive therapies have the potential of tumor eradication without undue damaging effect on normal tissues. In this context, methods based on the T cell receptor (TCR) engineering or chimeric antigen receptors (CARs) have shown great promise. This review focuses on the TCR-like CARs and TCR-CARs directed against tumor-derived epitopes, with a concerted view on neoepitopes. We also address the current limitations of the field to know how to harness the full benefits of this approach and thereby design a sustained and specific antitumor therapy.

Automated summary

Neoepitopes or neoantigens are unique mutations in a patient's tumor that can be used for tumor treatment. Adoptive therapies based on T cell receptor engineering or CARs show promise in eradicating tumors while minimizing damage to normal tissues. The focus is on neoepitopes and addressing current limitations in harnessing this approach for effective and specific anti-tumor therapy.